| [1] | (1994) Special considerations in studies of drug-induced birth defects. In: Strom B, editor. Pharmacoepidemiology. Chichester: Wiley. editor.
|
| [2] | Kennedy DL, Uhl K, Kweder SL (2004) Pregnancy exposure registries. Drug Saf 27: 215–228.
|
| [3] | Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (2002) Guidance for industry: Establishing pregnancy exposure registries. US Food and Drug Administration. Available: http://www.fda.gov/cber/gdlns/pregexp.ht？m. Accessed 10 August 2008.
|
| [4] | European Medicine Agency (2005) Guideline on the exposure to medicinal products during pregnancy: Need for post-authorisation data. Available: http://www.emea.europa.eu/pdfs/human/phv？wp/31366605en.pdf. Accessed 10 August 2008.
|
| [5] | Lang T, Hughes D, Kanyok T, Kengeya-Kayondo J, Marsh V, et al. (2006) Beyond registration—Measuring the public-health potential of new treatments for malaria in Africa. Lancet Infect Dis 6: 46–52.
|
| [6] | Staedke S (2005) Pharmacovigilance and antimalarial treatment in Africa: The practical challenges. The Newsletter of The East African Network for Monitoring Antimalarial Treatment 8: 2. Available: http://www.eanmat.org/Newsletters/Nwsltt？21.doc. Accessed 10 August 2008.
|
| [7] | Talisuna AO, Staedke SG, D'Alessandro U (2006) Pharmacovigilance of antimalarial treatment in Africa: Is it possible. Malar J 5: 50.
|
| [8] | Pirmohamed M, Atuah KN, Dodoo AN, Winstanley P (2007) Pharmacovigilance in developing countries. BMJ 335: 462.
|
| [9] | White NJ, McGready RM, Nosten FH (2008) New medicines for tropical diseases in pregnancy: Catch-22. PLoS Med 5: e133. doi:10.1371/journal.pmed.0050133.
|
| [10] | Steketee RW, Nahlen BL, Parise ME, Menendez C (2001) The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64: 28–35.
|
| [11] | Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, et al. (2007) Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 7: 93–104.
|
| [12] | World Health Organization (2006) Guidelines for the treatment of malaria. WHO/HTM/MAL/2006.1108. Available: http://www.who.int/malaria/includes_en/w？homalariapublications19982004.htm. Accessed 10 August 2008.
|
| [13] | McGready R, Cho T, Keo NK, Thwai KL, Villegas L, et al. (2001) Artemisinin antimalarials in pregnancy: A prospective treatment study of 539 episodes of multidrug-resistant . Clin Infect Dis 33: 2009–2016.
|
| [14] | Dellicour S, Hall S, Chandramohan D, Greenwood B (2007) The safety of artemisinins during pregnancy: A pressing question. Malar J 6: 15.
|
| [15] | Nosten F, McGready R, Alessandro U, Bonell A, Verhoeff F, et al. (2006) Antimalarial Drugs in Pregnancy: A Review. Curr Drug Saf 1: 1–15.
|
| [16] | Ward SA, Sevene EJ, Hastings IM, Nosten F, McGready R (2007) Antimalarial drugs and pregnancy: Safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis 7: 136–144.
|
| [17] | US Food and Drug Administration (2008) List of pregnancy exposure registries. Available: http://www.fda.gov/womens/registries/reg？istries.html. Accessed 10 August 2008.
|
| [18] | Warkary J (1974) Problems in applying teratologic observations in animals to man. Paediatrics 53: 820.
|
| [19] | Honein MA, Paulozzi LJ, Cragan JD, Correa A (1999) Evaluation of selected characteristics of pregnancy drug registries. Teratology 60: 356–364.
|
| [20] | Simpson JL (1990) Incidence and timing of pregnancy losses: Relevance to evaluating safety of early prenatal diagnosis. Am J Med Genet 35: 165–173.
|
| [21] | Andrews E, Stergachis A, Hecht J (1989) Evaluation of alternative methods of assessing pregnancy outcomes using automated indicators of pregnancy. J Clin Res Drug Dev 3: 201.
|
| [22] | Briggs GG (2002) Drug effects on the foetus and breast-fed infant. Clin Obstet Gynecol 45: 6–21.
|
| [23] | Christianson RE, van den Berg BJ, Milkovich L, Oechsli FW (1981) Incidence of congenital anomalies among white and black live births with long-term follow-up. Am J Public Health 71: 1333–1341.
|
| [24] | Siffel C, Correa A, Cragan J, Alverson CJ (2004) Prenatal diagnosis, pregnancy terminations and prevalence of Down syndrome in Atlanta. Birth Defects Res A Clin Mol Teratol 70: 565–571.
|
| [25] | Strom BL (2000) Pharmacoepidemiology. Sussex: John Wiley & Sons.
|
| [26] | Covington DL, Tilson H, Elder J, Doi P (2004) Assessing teratogenicity of antiretroviral drugs: Monitoring and analysis plan of the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 13: 537–545.
|
| [27] | Scheuerle A, Covington D (2004) Clinical review procedures for the Antiretroviral Pregnancy Registry. Pharmacoepidemiol Drug Saf 13: 529–536.
|
| [28] | Joint CIOMS/WHO Working Group (2005) Drug development research and pharmacovigilance in resource-poor countries. Available: http://www.cioms.ch/frame_whats_new.htm. Accessed 10 August 2008.
|
| [29] | Huff-Rouselle M, Simooya O, Kabwe V, Hollander I, Handema R, et al. (2007) Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond. Glob Pub Health 2: 184–203.
|
| [30] | Tilson J, Watts J, Covington D (2006) Effective use of supplemental data in pregnancy exposure registries [presentation]. 22nd International Conference on Pharmacoepidemiology & Risk Management; 24–27 August 2006; Lisbon, Portugal.
|
| [31] | Clark R, Kumemura M, Makori N, Nakata Y, Bernard F, et al. (2006) Artesunate: Developmental toxicity in monkeys [abstract]. 46th Annual Meeting of the Teratology Society; 24–29 June 2006; Tucson, Arizona, United States.
|
| [32] | Clark RL, White TE, A Clode S, Gaunt I, Winstanley P, et al. (2004) Developmental toxicity of artesunate and an artesunate combination in the rat and rabbit. Birth Defects Res B Dev Reprod Toxicol 71: 380–394.
|
| [33] | Longo M, Zanoncelli S, Manera D, Brughera M, Colombo P, et al. (2006) Effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos in vitro. Reprod Toxicol 21: 83–93.
|
| [34] | Longo M, Zanoncelli S, Della Torre P, Rosa F, Giusti A, et al. (2008) Investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX). Reprod Toxicol 25: 433–441.
|
| [35] | World Health Organization (2007) Assessment of the safety of artemisinin compounds in pregnancy: Report of two joint informal consultations convened in 2006. WHO/CDS/MAL/2003.1094. Available: http://www.who.int/tdr/publications/publ？ications/pdf/artemisinin_compounds_pregn？ancy.pdf. Accessed 10 August 2008.
|
| [36] | White TEK, Clark RL (2008) Sensitive periods for developmental toxicity of orally administered artesunate in the rat. Birth Defects Res B Dev Reprod Toxicol. E-pub 9 July 2008.
|
| [37] | World Health Organization (2004) World health statistics. Basic demographic and socio-economic indicators: Total fertility rate, female, for latest available data. WHO Global Health Atlas. Available: http://www.who.int/GlobalAtlas/. Accessed 10 August 2008.
|
| [38] | Say L, Donner A, Gulmezoglu AM, Taljaard M, Piaggio G (2006) The prevalence of stillbirths: A systematic review. Reprod Health 3: 1.
|
| [39] | McCombie SC (1996) Treatment seeking for malaria: A review of recent research. Soc Sci Med 43: 933–945.
|
| [40] | Hamer DH, Ndhlovu M, Zurovac D, Fox M, Yeboah-Antwi K, et al. (2007) Improved diagnostic testing and malaria treatment practices in Zambia. JAMA 297: 2227–2231.
|
| [41] | Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, et al. (2007) Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: Randomised trial. BMJ 334: 403.
|
